NASDAQ:CDT Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis $0.07 +0.01 (+13.87%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About Conduit Pharmaceuticals Stock (NASDAQ:CDT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CDT alerts:Sign Up Key Stats Today's Range$0.06▼$0.0850-Day Range$0.07▼$0.1352-Week Range$0.06▼$5.51Volume18.69 million shsAverage Volume10.03 million shsMarket Capitalization$7.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewConduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Read More… Receive CDT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CDT Stock News HeadlinesConduit Pharmaceuticals Faces Nasdaq Delisting, Plans Stock SplitDecember 21 at 12:26 AM | markets.businessinsider.comConduit and Sarborg link to optimise AI drug developmentDecember 14, 2024 | msn.comYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!December 21, 2024 | WealthPress (Ad)Conduit Pharmaceuticals to enter agreement with SARBORDecember 13, 2024 | markets.businessinsider.comConduit Collaborates With Sarborg To Facilitate Drug Development, Stock Up In Pre-MarketDecember 12, 2024 | markets.businessinsider.comConduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and CyberneticsDecember 12, 2024 | globenewswire.comConduit Pharmaceuticals receives further patent approval for AZD1656November 21, 2024 | markets.businessinsider.comWhat's Going On With Conduit Pharmaceuticals Shares Today?November 21, 2024 | benzinga.comSee More Headlines CDT Stock Analysis - Frequently Asked Questions How have CDT shares performed this year? Conduit Pharmaceuticals' stock was trading at $4.55 at the beginning of 2024. Since then, CDT stock has decreased by 98.4% and is now trading at $0.0747. View the best growth stocks for 2024 here. How do I buy shares of Conduit Pharmaceuticals? Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Conduit Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Conduit Pharmaceuticals investors own include BIOLASE (BIOL), Daré Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Cara Therapeutics (CARA), Canoo (GOEV) and Jiuzi (JZXN). Company Calendar Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDT Previous SymbolNASDAQ:CDT CUSIPN/A CIK1896212 Webwww.conduitpharma.com Phone760-471-8536FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-328.67% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-7.47Miscellaneous Outstanding Shares102,850,000Free Float67,119,000Market Cap$7.68 million OptionableNot Optionable Beta2.21 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:CDT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.